MediWound (NASDAQ:MDWD – Get Rating) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 30th. Analysts expect MediWound to post earnings of ($0.31) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.
MediWound (NASDAQ:MDWD – Get Rating) last issued its quarterly earnings data on Thursday, March 16th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.99). The firm had revenue of $11.62 million for the quarter, compared to the consensus estimate of $7.41 million. MediWound had a negative return on equity of 638.40% and a negative net margin of 73.97%. On average, analysts expect MediWound to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
MediWound Trading Down 1.1 %
Shares of MediWound stock opened at $9.67 on Tuesday. The stock has a market capitalization of $89.02 million, a price-to-earnings ratio of -2.52 and a beta of 1.06. MediWound has a 1-year low of $8.05 and a 1-year high of $15.72. The firm’s 50-day moving average price is $11.68 and its two-hundred day moving average price is $11.74.
Hedge Funds Weigh In On MediWound
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on MDWD. StockNews.com began coverage on shares of MediWound in a research note on Thursday, May 18th. They set a “hold” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of MediWound in a research report on Friday, March 17th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, MediWound has a consensus rating of “Moderate Buy” and a consensus price target of $32.33.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.
- Get a free copy of the StockNews.com research report on MediWound (MDWD)
- monday.com Surges on Price and Volume after Blowout Results
- Can Ryanair Stock Fly Above Resistance Levels, What Earnings Show
- All Aboard! The Sell-Side Has Railroads In Reversal
- Is There Value Left in Lyft Stock?
- Everything About ZIM Integrated Screams Undervaluation
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.